Comparing Arndt and Tappa Endobronchial Blocker During Pediatric One Lung Ventilation

Sponsor
Istanbul University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05417256
Collaborator
(none)
26
1
2
14.9
1.8

Study Details

Study Description

Brief Summary

This study aims to evaluate the efficacy and ease of placement of two different endobronchial blockers(Arndt and Tappa blocker) for pediatric patients undergoing thoracotomy. Time from laryngoscopy to successful insertion of the blocker by an experienced anaesthetist will be recorded and the difficulty of placement of the blocker will be assesed. We plan to evaluate the lung collapse and also observe the effect of two different bronchial blockers on patients' ventilation and oxygenation and adverse events such as desaturation, failed one lung ventilation.Our primary outcome is the time from laryngoscopy to successful insertion of the bronchial blocker by an experienced anaesthetist. Our secondary outcomes are effects of two different bronchial blockers on lung isolation score, ease of placement of the bronchial blocker, mechanical ventilation parameters (tidal volume, respiratory rate, peak airway pressure, plateau pressure, compliance), intraoperative blood gas analysis (paO2, pCO2, saO2, lac), frequency of malposition after successful blocker placement, surgical exposure and complications.

Condition or Disease Intervention/Treatment Phase
  • Device: Tappa Endobronchial Blocker
  • Device: Arndt Endobronchial Blocker
N/A

Detailed Description

Many techniques for one lung ventilation exist including the use of double-lumen tubes, endotracheal tubes and bronchial blockers. The choice of lung isolation technique depends on the age, the size of the patient, experience of the anaesthetist and type of the surgery. The use of double lumen tube for one lung ventilation is very common. However, it may be challenging and hazardous in some cases such as pediatric patients, patients with tracheostomy, difficult airway scenarios. Endobronchial blockers can be used for these cases. Bronchial blockers have high-volume,low-pressure balloons so they are less likely to cause damage to the airway mucosa while achieving a successful lung isolation. Arndt blocker has a low-pressure, high-volume balloon, a multiport airway adapter and a guide loop. On the other hand, Tappa bronchial blocker has an auto inflation balloon, and a high volume low pressure cuff. It also has 'Tappa angle' which is designed as per human anatomy which makes it easier to insert.

In our study, we aim to compare the efficacy and ease of placement of Arndt and Tappa blocker for pediatric one lung ventilation. Our primary outcome is the time from laryngoscopy to successful insertion of the bronchial blocker by an experienced anaesthetist. Secondary outcomes are effects of two different bronchial blockers on lung isolation score, ease of placement of the bronchial blocker, mechanical ventilation parameters (tidal volume, respiratory rate, peak airway pressure, plateau pressure, compliance), intraoperative blood gas analysis (paO2, pCO2, saO2, lac), frequency of malposition after successful blocker placement, surgical exposure and complications. The difficulty of placement of the blocker will be assesed by a 5-point scale (1:very easy, 5:impossible) and the lung collapse will be evaluated by using a 10-point scale (10: complete collapse).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
26 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Care Provider)
Primary Purpose:
Treatment
Official Title:
A Prospective Randomized Trial Comparing the Application of Arndt and Tappa Endobronchial Blocker During Pediatric One Lung Ventilation
Anticipated Study Start Date :
Jul 25, 2022
Anticipated Primary Completion Date :
Dec 25, 2022
Anticipated Study Completion Date :
Oct 20, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Tappa Blocker Group

After orotracheal intubation, Tappa endobronchial blocker will be inserted using a broncoscope by an experienced anaesthetist. Time from laryngoscopy to successful placement of the endobronchial blocker will be recorded.

Device: Tappa Endobronchial Blocker
After intubation, the Tappa bronchial blocker will be advanced either through the intubation tube or outside the tube using a fiberoptic broncoscope. Once the position of the blocker is confirmed, the cuff of the blocker will be inflated with 1-3 mL of air. Since Tappa blocker has an autoinflation system, the anaesthetist can both inflate the cuff with one hand and operate the fiberoptic broncoscope at the same time.

Active Comparator: Arndt Blocker Group

After orotracheal intubation, Arndt endobronchial blocker will be inserted using a broncoscope by the experienced anaesthetist. Time from laryngoscopy to successful placement of the endobronchial blocker will be recorded.

Device: Arndt Endobronchial Blocker
After intubation, the endobronchial blocker will be passed through a multiport airway adapter that is placed at the proximal end of the tracheal tube.The fiberoptic broncoscope will be passed through the port and then through the guidewire loop at the end of the blocker. The bronchial blocker and the broncoscope will be advanced as a single unit into the target part of a right or left lung. The broncoscope will be withdrawn into the trachea and the blocker cuff will be inflated and the position of the blocker will be confirmed using the fiberoptic broncoscope. The wire loop will be removed after correct placement of the blocker. Once the guide wire is removed, the blocker can't be replaced.

Outcome Measures

Primary Outcome Measures

  1. Time from laryngoscopy to placement of the bronchial blocker [Up to 30 minutes]

    Time from laryngoscopy to correct insertion of the bronchial blocker by an experienced anaesthetist will be recorded.

Secondary Outcome Measures

  1. Lung collapse score [Up to 30 minutes]

    Lung collapse will be assesed at 5,10,15,and 20 minutes after pleural opening using a 10-point scale by the surgeon. 1 point refers to the inflated lung and 10 point refers to a completely collapsed lung.

  2. Difficulty of placement [Up to 30 minutes]

    The anaesthetist will rate the difficulty of placement of the bronchial blocker using a 5-point scale, 1 point being very easy and 5 points being impossible to insert.

  3. Tidal volume [Up to 120 minutes]

    Volume of gas delivered during each ventilator breath.

  4. Respiratory rate [Up to 120 minutes]

    Number of breaths delivered by the ventilator per minute.

  5. Peak airway pressure [Up to 120 minutes]

    Pressure used to deliver tidal volume by overcoming resistance in airways and lungs .

  6. Plateau pressure [Up to 120 minutes]

    End inspiratory pressure during a period with no gas flow in the circuit.

  7. Compliance [Up to 120 minutes]

    Change in volume of the lung produced by a change in pressure across the lung.

  8. Partial pressure of oxygen [At 15 minutes after initiation of one lung ventilation.]

    Measurement of oxygen pressure in arterial blood.

  9. Partial pressure of carbon dioxide [At 15 minutes after initiation of one lung ventilation.]

    Measurement of carbon dioxide pressure in arterial blood.

  10. Lactate [At 15 minutes after initiation of one lung ventilation.]

    Lactate levels in arterial blood gas is used to evaluate tissue perfusion.

  11. Frequency of malposition of the bronchial blocker [Up to the end of one lung ventilation intraoperatively.]

    Frequency of malposition of the bronchial blocker after successful bronchial blocker placement will be recorded if the blocker displaces.

  12. Length of intensive care unit (ICU) stay [Up to 48 hours]

    If the patients stay in ICU postoperatively

  13. First mobilitisition time [Up to 24 hours]

    First mobilitisition time

  14. Length of hospital stay [Up to 1 week]

    Length of hospital stay

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Year to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Pediatric patients undergoing thoracic surgery

  • American Society of Anesthesiology Class 1-2-3

Exclusion Criteria:
  • Denial of patients or parents

  • Coagulopathy

  • With preexisting cardiac dysfunction

  • Wtih history of renal and/or hepatic dysfunction

Contacts and Locations

Locations

Site City State Country Postal Code
1 Istanbul University Istanbul Turkey

Sponsors and Collaborators

  • Istanbul University

Investigators

  • Principal Investigator: Meltem Savran Karadeniz, Assoc Prof, Istanbul University

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Meltem Savran Karadeniz, Associated Professor, Istanbul University
ClinicalTrials.gov Identifier:
NCT05417256
Other Study ID Numbers:
  • 2021/930
First Posted:
Jun 14, 2022
Last Update Posted:
Jun 14, 2022
Last Verified:
Jun 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Meltem Savran Karadeniz, Associated Professor, Istanbul University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 14, 2022